PAQ Therapeutics presents first Phase 1 clinical data for KRAS G12D degrader PT0253 at ENA 2026
PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.
Event / data period:
Published: · Updated:

PAQ Therapeutics, a clinical-stage biotechnology company based in Burlington, Massachusetts, announced on 20 November 2026 the first clinical data from its ongoing Phase 1 trial of PT0253, an investigational intravenous small-molecule degrader targeting the KRAS G12D mutant protein. The preliminary results from study NCT06797336 were presented in a late-breaking oral session by Alexander I. Spira of NEXT Oncology Virginia at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company stated that the findings reflect an October 23, 2026 clinical data cutoff.
In the monotherapy dose-escalation portion of the trial, 44 patients with KRAS G12D-mutant advanced solid tumors received weekly intravenous infusions of PT0253 at doses ranging from 10 to 750 mg. Enrolled patients had received a median of 2.5 prior lines of therapy, and 27 percent had previously been treated with a KRAS- or RAS-targeted agent. The trial is designed to evaluate safety and tolerability and to identify the maximally tolerated dose or recommended Phase 2 dose in adult patients with advanced KRAS G12D-mutant solid tumors.
Across the full evaluated monotherapy dose range of 10 to 750 mg, investigators observed no dose-limiting toxicities. Among the 27 patients treated at higher dose levels from 120 to 750 mg, treatment-related adverse events were predominantly Grade 1 or Grade 2 in severity. Only one patient, representing 4 percent of that cohort, experienced a Grade 3 or higher treatment-related adverse event. PAQ Therapeutics reported no serious treatment-related adverse events, no treatment discontinuations caused by treatment-related adverse events, and no requirement for PT0253-specific pre-treatment prophylaxis.
Monotherapy antitumor activity appeared across dose levels of 120 mg and higher in patients with colorectal, pancreatic and lung cancers. In refractory colorectal cancer, three of six patients treated at 120 mg or above achieved unconfirmed partial responses, including one patient whose tumor had previously progressed on a KRAS-targeted therapy. PAQ Therapeutics noted that these early observations are consistent with the scientific hypothesis that catalytic degradation of KRAS G12D may counter EGFR-mediated feedback reactivation seen with conventional KRAS inhibitors, though confirmation in larger cohorts remains necessary.
In the pancreatic cancer monotherapy subgroup treated at 120 mg and above, three of ten patients who had not previously received KRAS- or RAS-targeted therapy achieved confirmed partial responses, with most responses deepening over time, and nine of ten patients achieved disease control. Separately, among 12 patients across the study whose disease had progressed on prior KRAS- or RAS-targeted therapies, six patients, or 50 percent, achieved disease control. Because these subgroups remain small and early-stage, the company cautioned that preliminary Phase 1 figures are subject to ongoing monitoring and may shift as follow-up matures.
PAQ Therapeutics also presented initial combination data in first-line metastatic pancreatic cancer, where 14 patients received weekly PT0253 at 350 mg alongside modified FOLFIRINOX, a standard-of-care multi-agent chemotherapy regimen. As of the October 23, 2026 cutoff, 13 of those 14 patients remained on treatment. Among the seven patients who had completed at least two post-baseline tumor scans, six achieved objective responses, comprising one confirmed complete response and five partial responses, four of which were confirmed.
The combination regimen was reported to be generally well tolerated, with a safety profile consistent with modified FOLFIRINOX alone and low gastrointestinal toxicity without PT0253-specific pre-treatment prophylaxis. Median relative dose intensity reached 91 percent for PT0253, while modified FOLFIRINOX dose intensity ranged from 75 to 80 percent across its chemotherapy components, matching the expected clinical range for the regimen. Maintaining standard chemotherapy dose intensity is a key practical test for investigational first-line pancreatic cancer add-on agents.
Chief executive officer Nan Ji said the early safety profile, single-agent antitumor signals and initial combination activity support advancing PT0253 into pancreatic and colorectal cancer expansion cohorts. Chief medical officer Andrew P. Krivoshik highlighted the absence of dose-limiting toxicities and the preservation of expected chemotherapy dose intensity as evidence of combinability. Presenter Alexander I. Spira noted that patients with KRAS G12D-mutant tumors who progress after chemotherapy and KRAS-targeted drugs have limited options, adding that expansion cohorts will be essential to evaluate these preliminary signals.
Beyond PT0253, PAQ Therapeutics is conducting Phase 1 clinical testing of PT0511, an investigational pan-KRAS protein degrader for advanced solid tumors. Neither compound has regulatory approval, and the ENA 2026 disclosure represents an early-stage, non-randomized dataset from a small number of evaluable patients. Confirmation of unconfirmed responses, durability of tumor shrinkage, progression-free survival and safety over longer treatment exposure in upcoming expansion cohorts will be needed before pivotal clinical development can be assessed.
Data
Key reported figures
Selected preliminary Phase 1 monotherapy and combination clinical figures for PT0253 as of the October 23, 2026 data cutoff.
- Patients treated in PT0253 monotherapy dose escalation
- 44 patients
- 2026-10-23 · Observed
- Rate of Grade 3 or higher treatment-related adverse events at 120-750 mg
- 4 percent
- 2026-10-23 · Observed
- Disease control rate in patients after prior KRAS/RAS-targeted therapy
- 50 percent
- 2026-10-23 · Observed
- First-line pancreatic cancer patients treated with PT0253 plus mFOLFIRINOX
- 14 patients
- 2026-10-23 · Observed
- Median relative dose intensity of PT0253 in combination cohort
- 91 percent
- 2026-10-23 · Observed
Methodology
Figures retain the source's stated cohorts, data cutoff and definitions. Early Phase 1 results are preliminary and subject to ongoing monitoring. No missing value is inferred.
Updated:
Subjects and places
Subject proposals
- CancerSuggested
- Subject suggested from the title or summary: cancerwww.prnewswire.com ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- United States · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.prnewswire.com ↗